US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Sensei Biotherapeutics, Inc. - Common Stock (NQ:SNSE)

13.85 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sensei Biotherapeutics, Inc. - Common Stock

News headline image
Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
From Sensei Biotherapeutics, Inc.
Via Business Wire
News headline image
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sensei Biotherapeutics, Inc.
Via Business Wire
News headline image
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Sensei Biotherapeutics, Inc.
Via Business Wire
News headline image
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
From World Street Intelligence
Via GlobeNewswire
News headline image
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
From Sensei Biotherapeutics, Inc.
Via Business Wire
News headline image
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
From Sensei Biotherapeutics, Inc.
Via Business Wire
News headline image
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
From Sensei Biotherapeutics, Inc.
Via Business Wire
News headline image
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sensei Biotherapeutics, Inc.
Via Business Wire
News headline image
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sensei Biotherapeutics, Inc.
Via Business Wire
News headline image
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
From Sensei Biotherapeutics, Inc.
Via Business Wire
News headline image
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
From Egle Therapeutics
Via GlobeNewswire
News headline image
Newman Ferrara LLP Announces Corporate Governance Investigations of Sensei Biotherapeutics, Inc. (SNSE)
From Newman Ferrara LLP
Via Business Wire
News headline image
Significant Investor in Sensei Biotherapeutics, Inc. Urges Board to Seek Shareholder Mandate
From Apeiron Investment Group Ltd.
Via GlobeNewswire